முறையான மெட்டா பகுப்பாய்வு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from முறையான மெட்டா பகுப்பாய்வு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In முறையான மெட்டா பகுப்பாய்வு Today - Breaking & Trending Today

Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.
The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx, a leading drug-eluting stent (DES). The primary endpoint of the study is target lesion failure at one year. Secondary endpoints include measures of the implants ability to accommodate vessel growth from disease progression and restore artery pulsatility in an imaging subset, as well as other major c ....

United States , Coll Cardiol , Michelle Mcadam , Kostenloser Wertpapierhandel , Shigeru Saito , Stefan Verheye , Austrian Wiktor Stent Study Group , Antwerp Cardiovascular Centre , Elixir Medical Corporation , Catheterization Laboratory At Shonan Kamakura , Chronic Communications Inc , Elixir Medical , Dynamx Coronary Bioadaptor System , Dynamx Bioadaptor , Resolute Onyx , Catheterization Laboratory , Shonan Kamakura General Hospital , Antwerp Cardiovascular , Medical Corporation , Varying Outcomes With , Absorb Bioresorbable Vascular Scaffold During , Year Follow Up , Systematic Meta Analysis , Individual Patient Data Pooled , Randomized Controlled Trial , Paclitaxel Eluting Stents ,

Elixir Medical's 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events

Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
January 28, 2021
The DynamX Bioadaptor is a new class of treatment for Coronary Artery Disease.
SINGAPORE, January 28, 2021 /EINPresswire.com/ Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, recently presented at 30th Annual Live Interventions in Vascular Endotherapy conference organised by the National Heart Centre of Singapore (Singapore LIVE). The bioadaptor is the first coronary artery implant that adapts to vessel physiology. ....

United States , Sri Lanka , Soo Teik , National Heart Centre Singapore , Department Of Cardiology , Catheterisation Laboratory In Columbus Hospital , Elixir Medical Corporation , Catheterisation Laboratory , National Heart Centre , Professor Of Cardiology At Humanitas Medical School , Singapore Heart Foundation , National Heart Centre Of Singapore , Mileage Communications Pte Ltd , Dynamx Bioadaptor , Coronary Artery , Elixir Medical , Month Clinical Results , Dynamx Bioadaptor Showed Strong Safety Profile , With No Clinical , Coronary Bioadaptor System , Annual Live Interventions , Antonio Colombo , Humanitas Medical School , Senior Consultant , Interventional Cardiology , Humanitas Research Hospital ,